NIJMEGEN, Netherlands,
July 11, 2024 /PRNewswire/ -- MGI
(MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI),
a company committed to building core tools and technologies that
drive innovation in life science, today announced the collaboration
with Predica Diagnostics, a leading innovator in oncology
diagnostics, to develop Predica's targeted RNA sequencing tests on
the cost-effective MGI Next-generation sequencing platforms.
The collaboration seeks to revolutionize molecular diagnostics
by enabling early cancer detection and facilitating personalized
targeted treatment strategies. By combining Predica Diagnostics'
advanced sequencing assays with MGI's state-of-the-art
Next-generation sequencing platforms, the initiative promises a
rapid, accurate, and affordable solution for healthcare
providers.
Empowering Precision Medicine
Predica Diagnostics, renowned for its expertise in cervical
cancer screening through its proprietary ciRNAseq-based test,
CervicaDx, brings unparalleled precision in identifying high-risk
HPV oncogenes and other (pre)malignancy biomarkers. By integrating
this advanced diagnostic capability with MGI's robust and
affordable DNBSEQ technology, the partnership aims to significantly
enhance the accuracy and accessibility of diagnostic tests.
Enhancing Affordability and Accessibility
A core value of this partnership is making high-quality
diagnostic and predictive testing more affordable and accessible.
MGI Tech's DNBSEQ platforms, recognized for their cost-efficiency
and scalability, will enable healthcare institutions to offer
advanced genomic and transcriptomic testing at a lower cost.
Compared to existing NGS-based technologies, MGI's platform offers
cost-effective and faster results. Within the collaboration, MGI's
NGS platform will be deployed for conducting the final analysis of
Predica's disruptive, ciRNAseq-based targeted RNA sequencing tests.
This combination will help researchers and healthcare professionals
to better predict patient prognosis and guide treatment with
precision medicines.
A Shared Vision for the Future
"Predica welcomes MGI as a partner with expertise that is highly
synergistic with that of Predica", says Dr. William Leenders, CSO of Predica Diagnostics.
"Where our expertise lies in providing smart molecular diagnostic
solutions for unmet medical needs, we see the combination with MGIs
sequencing platforms as a perfect match for customers to get
clinically important information on gene expression without the
need for any on-site bio-informatic expertise."
Dr. Yong Hou, General Manager of
MGI Europe and Africa, adds, "This
partnership embodies our commitment to advancing healthcare through
innovative genomic solutions. By combining our affordable and
high-performance sequencing technology with Predica's expert
diagnostic kits, we are poised to make a significant impact in the
field of personalized medicine."
MGI Tech Co., Ltd. (or its subsidiaries, together
referred to MGI) is committed to building core tools and
technologies that drive innovation in life science. Our focus lies
in research & development, manufacturing, and sales of
instruments, reagents, and related products in the field of life
science and biotechnology. We provide real-time, multi-omics,
and full spectrum of digital equipment and systems for precision
medicine, agriculture, healthcare and various other industries.
Founded in 2016, MGI has grown into a leader in life science,
serving customers across six continents and has established
research, manufacturing, training, and after-sales service
facilities globally. MGI stands out as one of the few companies
capable of independently developing and mass-producing
clinical-grade gene sequencers with varying throughput capacities,
ranging from Gb to Tb levels. With unparalleled expertise,
cutting-edge products, and a commitment to global impact, MGI
continues to shape the trajectory of life sciences into the future.
To learn more, please visit https://en.mgi-tech.com/, LinkedIn, X,
and YouTube.
Predica Diagnostics B.V is a spinoff from the Radboud
UMC, active in the field of diagnostics, prognostics and prediction
of treatment response in oncology. Predica Diagnostics aims to
bring its ciRNAseq technology to patients in 1 to 2 years with a
first focus on the CervicaDx test for improved cervical cancer
screening. The test allows non-invasive detection of cervical
abnormalities with unprecedented specificity in women with a
positive HPV test. Other tests in development concern tests to
detect host-microbiome interactions and tests to detect activity of
biological pathways and mutations that are amenable for targeted
treatment with precision medicines, enabling the development of
personalized treatment plans for cancer patients.
Logo -
https://mma.prnewswire.com/media/2329841/MGI__Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/mgi-tech-and-predica-diagnostics-team-up-for-precision-rna-sequencing-in-oncology-302194629.html